Efficacy and safety of aliskiren-based dual and triple combination therapies in US minority patients with stage 2 hypertension

Journal of the American Society of Hypertension

Volumn 5, Issue 2, 2011, Pages 102-113

  Ferdinand, Keith C ^a   Weitzman, Richard ^b   Israel, Marc ^b   Lee, Joleen ^b   Purkayastha, Das ^b   Jaimes, Edgar A ^c  

^a EMORY UNIVERSITY   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

amlodipine; Blacks; Hispanics; hydrochlorothiazide

Indexed keywords

ALISKIREN; ALISKIREN PLUS AMLODIPINE; ALISKIREN PLUS AMLODIPINE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; HYDROCHLOROTHIAZIDE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ARTICLE; BODY MASS; COMBINATION CHEMOTHERAPY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MINORITY GROUP; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; UNSPECIFIED SIDE EFFECT;

AFRICAN CONTINENTAL ANCESTRY GROUP; AMIDES; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG MONITORING; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; FUMARATES; HISPANIC AMERICANS; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 79952733572     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2011.01.006     Document Type: Article

References (38)

1. Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008;52:818-27.
2. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, de Simone G, et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 2010;121:e46-215.
3. Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm RH Jr, et al. Management of high blood pressure in blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension 2010;56:780-800.
4. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010;303:2043-50.
5. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52. (Pubitemid 37553153)
6. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87. (Pubitemid 46924065)
7. National Institute for Health and Clinical Excellence. Hypertension. Management of hypertension in adults in primary care. NICE clinical guideline 34. 2006. Available at: http://www.nice.org.uk/nicemedia/pdf/ cg034niceguideline.pdf (accessed June 1, 2008).
8. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 2002;39:E1-8.
9. Azizi M, Ménard J, Bissery A, Guyene TT, Bura-Rivière A. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. Clin J Am Soc Nephrol 2007;2:947-55.
10. Sanoski CA. Aliskiren: an oral direct renin inhibitor for the treatment of hypertension. Pharmacotherapy 2009;29:193-212.
11. Brown MJ. Aliskiren. Circulation 2008;118:773-84.
12. Drummond W, Munger MA, Rafique EM, Maboudian M, Khan M, Keefe DL. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens (Greenwich) 2007;9:742-50.
13. Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Smith B, Weissbach N, et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 2009;119:417-25.
14. Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Bush C, Keefe DL. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial. J Hypertens 2009;27:1493-501.
15. Duprez DA, Munger MA, Botha J, Keefe DL, Charney AN. Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. J Hum Hypertens 2009;24:600-8.
16. Littlejohn TW III, Trenkwalder P, Hollanders G, Zhao Y, Liao W. Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension. Curr Med Res Opin 2009;25:951-9.
17. Black HR, Weinberger M, Purkayastha D, Lee J, Israel M, Hilkert R, et al. Combination aliskiren/amlodipine is more effective than amlodipine monotherapy in male and female African American subjects with stage 2 hypertension. Presented at the 25th Annual Scientific Meeting and Exposition of the American Society of Hypertension. May 1-4, 2010, New York, NY. Poster PO-20.
18. Black HR, Weinberger M, Purkayastha D, Lee J, Israel M, Hilkert R, et al. Combination therapy with aliskiren/ amlodipine provides greater reductions in clinic and 24-hour ambulatory blood pressures than amlodipine alone in African Americans with stage 2 hypertension. Presented at the 25th Annual Scientific Meeting and Exposition of the American Society of Hypertension. May 1-4, 2010, New York, NY. Poster PO-19.
19. Weinberger M, Izzo JL, Purkayastha D, Lee J, Israel M, Hilkert R, et al. Combination aliskiren/amlodipine provides greater blood pressure reduction than amlodipine monotherapy in African American subjects with stage 2 hypertension and obesity or metabolic syndrome. Presented at the 25th Annual Scientific Meeting and Exposition of the American Society of Hypertension. May 1-4, 2010, New York, NY. Poster PO-64.
20. Frohlich ED, Grim C, Labarthe DR, Maxwell MH, Perloff D, Weidman WH. Recommendations for human blood pressure determination by sphygmomanometers: report of a special task force appointed by the Steering Committee, American Heart Association. Hypertension 1988;11:210A-22A.
21. Jamerson KA, Basile J. Prompt, aggressive BP lowering in high-risk patients. J Clin Hypertens (Greenwich) 2008;10(1 Suppl. 1):40-8.
22. Cooper-DeHoff RM, Aranda JM Jr, Gaxiola E, Cangiano JL, Garcia-Barreto D, Conti CR, et al. Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients - findings from the International Verapamil SR/Trandolapril Study (INVEST). Am Heart J 2006;151:1072-9.
23. Calhoun D, Glazer R, Yen J, Lacourciere Y. Effect of age, gender, race and ethnicity on efficacy of amlodipine/ valsartan/hydrochlorothiazide triple combination therapy in patients with moderate to severe hypertension. Presented at the 24th Annual Scientific Meeting and Exposition of the American Society of Hypertension. May 6-9, 2009, San Francisco, CA. Poster P-266.
24. Flack JM, Calhoun DA, Satlin L, Barbier M, Hilkert R, Brunel P. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. J Hum Hypertens 2009;23:479-89.
25. Oparil S, Chrysant SG, Melino M, Lee J, Karki S, Heyrman R. Long-term efficacy of a combination of amlodipine and olmesartan medoxomil+/- hydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: a substudy of the COACH trial. J Hum Hypertens 2010;24:831-8.
26. Taylor H, Liu J, Wilson G, Golden SH, Crook E, Brunson CD, et al. Distinct component profiles and high risk among African Americans with metabolic syndrome: the Jackson Heart Study. Diabetes Care 2008;31:1248-53.
27. Differences in prevalence of obesity among black, white, and Hispanic adults - United States, 2006-2008. MMWR 2009;58:740-4.
28. White WB. Importance of blood pressure control over a 24-hour period. J Manag Care Pharm 2007; 13(8 Suppl B):34-9.
29. Basile J. New therapeutic options in patients prone to hypertension: a focus on direct renin inhibition and aldosterone blockade. Am J Med Sci 2009;337:438-44.
30. Stanton AV, Gradman AH, Schmieder RE, Nussberger J, Sarangapani R, Prescott MF. Aliskiren monotherapy does not cause paradoxical blood pressure rises: meta-analysis of data from 8 clinical trials. Hypertension 2010;55:54-60.
31. Szuba A, Podgórski M. Asymmetric dimethylarginine (ADMA) a novel cardiovascular risk factor - evidence from epidemiological and prospective clinical trials. Pharmacol Rep 2006;58(Suppl):16-20.
32. Madero M, Sarnak MJ. Association of cystatin C with adverse outcomes. Curr Opin Nephrol Hypertens 2009;18:258-63.
33. Morrow JD. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol 2005;25:279-86.
34. Whaley-Connell A, Purkayastha D, Ricks ZA, Yadao A, Sowers JR. Combination therapy with aliskiren and HCTZ decreases plasma renin activity and oxidative stress versus ramipril while reducing blood pressure in obese patients with stage 2 hypertension. Presented at the 25th Annual Scientific Meeting and Exposition of the American Society of Hypertension. May 1-4, 2010, New York, NY. Poster PO-66.
35. Messerli FH, Bangalore S. Antihypertensive efficacy of aliskiren: is hydrochlorothiazide an appropriate benchmark? Circulation 2009;119:371-3.
36. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-28.
37. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
38. Ernst ME, Carter BL, Basile JN. All thiazide-like diuretics are not chlorthalidone: putting the ACCOMPLISH study into perspective. J Clin Hypertens 2009;11:5-10.